Can Histogenics Corporation (HSGX)’s Tomorrow Be Different? The Stock Increases Again

March 14, 2018 - By Ellis Scott

The stock of Histogenics Corporation (NASDAQ:HSGX) is a huge mover today! The stock increased 7.80% or $0.22 during the last trading session, reaching $3.04. About 346,257 shares traded or 132.75% up from the average. Histogenics Corporation (NASDAQ:HSGX) has declined 7.61% since March 14, 2017 and is downtrending. It has underperformed by 24.31% the S&P500.
The move comes after 7 months positive chart setup for the $74.70 million company. It was reported on Mar, 14 by We have $3.13 PT which if reached, will make NASDAQ:HSGX worth $2.24 million more.

Analysts await Histogenics Corporation (NASDAQ:HSGX) to report earnings on March, 15 before the open. They expect $-0.31 EPS, up 80.63 % or $1.29 from last year’s $-1.6 per share. After $-0.23 actual EPS reported by Histogenics Corporation for the previous quarter, Wall Street now forecasts 34.78 % negative EPS growth.

Histogenics Corporation (NASDAQ:HSGX) Ratings Coverage

Among 6 analysts covering Histogenics Corp (NASDAQ:HSGX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Histogenics Corp had 16 analyst reports since August 27, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Thursday, December 21. The rating was maintained by Canaccord Genuity with “Buy” on Friday, November 13. The stock has “Hold” rating by Zacks on Thursday, August 27. The firm earned “Buy” rating on Friday, August 12 by BTIG Research. The firm earned “Buy” rating on Monday, September 19 by Needham. As per Thursday, November 2, the company rating was maintained by H.C. Wainwright. As per Wednesday, September 7, the company rating was downgraded by William Blair. The firm earned “Buy” rating on Monday, October 16 by Canaccord Genuity. The firm earned “Neutral” rating on Friday, November 13 by BTIG Research. H.C. Wainwright maintained it with “Buy” rating and $3.5 target in Wednesday, December 27 report.

More notable recent Histogenics Corporation (NASDAQ:HSGX) news were published by: which released: “Histogenics Corporation Announces Closing of Underwritten Registered Direct …” on January 25, 2018, also with their article: “Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President …” published on October 12, 2017, published: “Form 4 HISTOGENICS CORP For: Feb 16 Filed by: Gridley Adam” on February 21, 2018. More interesting news about Histogenics Corporation (NASDAQ:HSGX) were released by: and their article: “S Squared Technology, LLC Buys Rapid7 Inc, Histogenics Corp, Adtran Inc, Sells …” published on February 13, 2018 as well as‘s news article titled: “Histogenics Corp. HSGX (US: Nasdaq)” with publication date: December 01, 2014.

Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company has market cap of $74.70 million. The firm offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It currently has negative earnings. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: